Conformational exchange in the potassium channel blocker ShK.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 12 2019
Historique:
received: 28 09 2019
accepted: 21 11 2019
entrez: 19 12 2019
pubmed: 19 12 2019
medline: 6 11 2020
Statut: epublish

Résumé

ShK is a 35-residue disulfide-linked polypeptide produced by the sea anemone Stichodactyla helianthus, which blocks the potassium channels Kv1.1 and Kv1.3 with pM affinity. An analogue of ShK has been developed that blocks Kv1.3 > 100 times more potently than Kv1.1, and has completed Phase 1b clinical trials for the treatment of autoimmune diseases such as psoriasis and rheumatoid arthritis. Previous studies have indicated that ShK undergoes a conformational exchange that is critical to its function, but this has proved difficult to characterise. Here, we have used high hydrostatic pressure as a tool to increase the population of the alternative state, which is likely to resemble the active form that binds to the Kv1.3 channel. By following changes in chemical shift with pressure, we have derived the chemical shift values of the low- and high-pressure states, and thus characterised the locations of structural changes. The main difference is in the conformation of the Cys17-Cys32 disulfide, which is likely to affect the positions of the critical Lys22-Tyr23 pair by twisting the 21-24 helix and increasing the solvent exposure of the Lys22 sidechain, as indicated by molecular dynamics simulations.

Identifiants

pubmed: 31848433
doi: 10.1038/s41598-019-55806-3
pii: 10.1038/s41598-019-55806-3
pmc: PMC6917819
doi:

Substances chimiques

Cnidarian Venoms 0
Kv1.3 Potassium Channel 0
Peptides 0
Potassium Channel Blockers 0
ShK neurotoxin 0
Kv1.1 Potassium Channel 147173-20-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19307

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/J014966/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R000727/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P020038/1
Pays : United Kingdom

Références

J Pharmacol Exp Ther. 2012 Sep;342(3):642-53
pubmed: 22637724
Biochemistry. 2014 Jan 28;53(3):447-9
pubmed: 24401037
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
pubmed: 9757107
Biophys J. 2011 Dec 7;101(11):2652-60
pubmed: 22261053
Proteins. 1995 Mar;21(3):167-95
pubmed: 7784423
PLoS One. 2017 Jul 19;12(7):e0180762
pubmed: 28723914
Biochemistry. 2002 Oct 8;41(40):11963-71
pubmed: 12356296
Mar Drugs. 2015 Jan 16;13(1):529-42
pubmed: 25603346
Eur J Biochem. 1998 Jan 15;251(1-2):133-41
pubmed: 9492277
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9
pubmed: 17088564
J Am Chem Soc. 2013 Aug 14;135(32):11911-9
pubmed: 23919482
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9615-20
pubmed: 17535901
J Phys Chem B. 2012 Apr 26;116(16):4812-22
pubmed: 22480371
Nat Struct Biol. 1996 Apr;3(4):317-20
pubmed: 8599755
J Phys Chem B. 2015 Dec 10;119(49):15130-7
pubmed: 26551165
J Clin Invest. 2003 Jun;111(11):1703-13
pubmed: 12782673
Prog Nucl Magn Reson Spectrosc. 2013 May;71:35-58
pubmed: 23611314
Annu Rev Biophys. 2012;41:63-79
pubmed: 22224600
Immunol Rev. 2009 Sep;231(1):59-87
pubmed: 19754890
Sci Rep. 2014 Mar 28;4:4509
pubmed: 24676092
Chem Sci. 2018 Jul 5;9(31):6548-6556
pubmed: 30310586
J Biomol NMR. 2016 Sep;66(1):37-53
pubmed: 27566173
Biochemistry. 1996 Dec 24;35(51):16407-11
pubmed: 8987971
Curr Opin Chem Biol. 2017 Jun;38:97-107
pubmed: 28412597
Chembiochem. 2014 Nov 3;15(16):2402-10
pubmed: 25236806
Future Med Chem. 2014 Oct;6(15):1645-58
pubmed: 25406005
Toxicon. 2012 Oct;60(5):840-50
pubmed: 22659540
J Biomol NMR. 2013 Jul;56(3):227-41
pubmed: 23728592
Biochemistry. 1993 Apr 13;32(14):3571-82
pubmed: 7682109
Toxicon. 1995 May;33(5):603-13
pubmed: 7660365
Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):350-358
pubmed: 30366154
Chem Rev. 2006 May;106(5):1814-35
pubmed: 16683756
J Biol Chem. 1999 Jul 30;274(31):21885-92
pubmed: 10419508
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4685-90
pubmed: 18326625
Structure. 2017 Dec 5;25(12):1856-1866.e2
pubmed: 29153504
Biochemistry. 1999 Nov 2;38(44):14549-58
pubmed: 10545177
Biochem Biophys Res Commun. 1996 Feb 27;219(3):696-701
pubmed: 8645244

Auteurs

Naoto Iwakawa (N)

Department of Molecular Engineering, Graduate School of Engineering, Kyoto University, Kyoto-Daigaku Katsura, Nishikyo-Ku, Kyoto, 615-8510, Japan.
Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.

Nicola J Baxter (NJ)

Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.

Dorothy C C Wai (DCC)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.

Nicholas J Fowler (NJ)

Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.

Rodrigo A V Morales (RAV)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.
CSL Limited (Bio21), 30 Flemington Road, Parkville, Victoria, 3010, Australia.

Kenji Sugase (K)

Department of Molecular Engineering, Graduate School of Engineering, Kyoto University, Kyoto-Daigaku Katsura, Nishikyo-Ku, Kyoto, 615-8510, Japan.

Raymond S Norton (RS)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia. ray.norton@monash.edu.
ARC Centre for Fragment-Based Design, Monash University, Parkville, Victoria, 3052, Australia. ray.norton@monash.edu.

Mike P Williamson (MP)

Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK. m.williamson@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH